Tibet Rhodiola Pharmaceutical Holding Co (600211) - Net Assets

Latest as of March 2026: CN¥4.23 Billion CNY ≈ $618.65 Million USD

Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has net assets worth CN¥4.23 Billion CNY (≈ $618.65 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.39 Billion ≈ $935.32 Million USD) and total liabilities (CN¥2.16 Billion ≈ $316.67 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Tibet Rhodiola Pharmaceutical Holding Co tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.23 Billion
% of Total Assets	66.14%
Annual Growth Rate	20.68%
5-Year Change	57.49%
10-Year Change	532.89%
Growth Volatility	90.11

Tibet Rhodiola Pharmaceutical Holding Co - Net Assets Trend (1996–2025)

This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Tibet Rhodiola Pharmaceutical Holding Co to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Tibet Rhodiola Pharmaceutical Holding Co (1996–2025)

The table below shows the annual net assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2025. For live valuation and market cap data, see how much is Tibet Rhodiola Pharmaceutical Holding Co worth.

Year	Net Assets	Change
2025-12-31	CN¥4.17 Billion ≈ $609.56 Million	+5.40%
2024-12-31	CN¥3.95 Billion ≈ $578.32 Million	+17.15%
2023-12-31	CN¥3.37 Billion ≈ $493.67 Million	+11.31%
2022-12-31	CN¥3.03 Billion ≈ $443.50 Million	+14.58%
2021-12-31	CN¥2.65 Billion ≈ $387.05 Million	+2.19%
2020-12-31	CN¥2.59 Billion ≈ $378.76 Million	+5.79%
2019-12-31	CN¥2.45 Billion ≈ $358.04 Million	+8.40%
2018-12-31	CN¥2.26 Billion ≈ $330.29 Million	+10.35%
2017-12-31	CN¥2.05 Billion ≈ $299.31 Million	+210.76%
2016-12-31	CN¥658.19 Million ≈ $96.31 Million	+35.46%
2015-12-31	CN¥485.90 Million ≈ $71.10 Million	+17.32%
2014-12-31	CN¥414.18 Million ≈ $60.61 Million	+3.75%
2013-12-31	CN¥399.20 Million ≈ $58.42 Million	+3.57%
2012-12-31	CN¥385.44 Million ≈ $56.40 Million	+8.59%
2011-12-31	CN¥354.94 Million ≈ $51.94 Million	+9.48%
2010-12-31	CN¥324.19 Million ≈ $47.44 Million	+8.06%
2009-12-31	CN¥300.00 Million ≈ $43.90 Million	+7.47%
2008-12-31	CN¥279.15 Million ≈ $40.85 Million	+1.78%
2007-12-31	CN¥274.28 Million ≈ $40.14 Million	-30.80%
2006-12-31	CN¥396.34 Million ≈ $58.00 Million	+0.79%
2005-12-31	CN¥393.25 Million ≈ $57.54 Million	-9.70%
2004-12-31	CN¥435.51 Million ≈ $63.73 Million	+2.59%
2003-12-31	CN¥424.53 Million ≈ $62.12 Million	+1.36%
2002-12-31	CN¥418.85 Million ≈ $61.29 Million	+3.04%
2001-12-31	CN¥406.50 Million ≈ $59.48 Million	+1.03%
2000-12-31	CN¥402.35 Million ≈ $58.88 Million	+3.24%
1999-12-31	CN¥389.71 Million ≈ $57.03 Million	+285.93%
1998-12-31	CN¥100.98 Million ≈ $14.78 Million	+18.33%
1997-12-31	CN¥85.34 Million ≈ $12.49 Million	+376.84%
1996-12-31	CN¥17.90 Million ≈ $2.62 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Tibet Rhodiola Pharmaceutical Holding Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 250138699600.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥2.50 Billion	65.85%
Common Stock	CN¥322.32 Million	8.49%
Other Comprehensive Income	CN¥234.00 Million	6.16%
Other Components	CN¥740.72 Million	19.50%
Total Equity	CN¥3.80 Billion	100.00%

Tibet Rhodiola Pharmaceutical Holding Co Competitors by Market Cap

The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their market capitalization.

Company	Market Cap
Eco World Develop Group KLSE:8206	$1.74 Billion
Tri Continental Closed Fund NYSE:TY	$1.74 Billion
Guangzhou Goaland Energy Conservation Tech Co Ltd SHE:300499	$1.74 Billion
H2O America NASDAQ:HTO	$1.74 Billion
MCC Meili Paper Industry Co Ltd SHE:000815	$1.74 Billion
Integral Ad Science Holding LLC NASDAQ:IAS	$1.74 Billion
Harbin Boshi Automation Co Ltd SHE:002698	$1.73 Billion
Kingsignal Technology Co Ltd SHE:300252	$1.73 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tibet Rhodiola Pharmaceutical Holding Co's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 3,917,817,000 to 3,798,429,273, a change of -119,387,727 (-3.0%).
Net income of 937,931,435 contributed positively to equity growth.
Dividend payments of 617,513,220 reduced retained earnings.
Other comprehensive income decreased equity by 13,853,766.
Other factors decreased equity by 425,952,176.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥937.93 Million	+24.69%
Dividends Paid	CN¥617.51 Million	-16.26%
Other Comprehensive Income	CN¥-13.85 Million	-0.36%
Other Changes	CN¥-425.95 Million	-11.21%
Total Change	CN¥-	-3.05%

Book Value vs Market Value Analysis

This analysis compares Tibet Rhodiola Pharmaceutical Holding Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.12x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 565.53x to 3.12x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1996-12-31	CN¥0.07	CN¥36.80	x
1997-12-31	CN¥0.31	CN¥36.80	x
1998-12-31	CN¥0.35	CN¥36.80	x
1999-12-31	CN¥1.42	CN¥36.80	x
2000-12-31	CN¥1.46	CN¥36.80	x
2001-12-31	CN¥1.47	CN¥36.80	x
2002-12-31	CN¥1.51	CN¥36.80	x
2003-12-31	CN¥1.53	CN¥36.80	x
2004-12-31	CN¥1.55	CN¥36.80	x
2005-12-31	CN¥1.40	CN¥36.80	x
2006-12-31	CN¥1.85	CN¥36.80	x
2007-12-31	CN¥1.26	CN¥36.80	x
2008-12-31	CN¥1.38	CN¥36.80	x
2009-12-31	CN¥1.56	CN¥36.80	x
2010-12-31	CN¥1.19	CN¥36.80	x
2011-12-31	CN¥1.66	CN¥36.80	x
2012-12-31	CN¥1.82	CN¥36.80	x
2013-12-31	CN¥1.47	CN¥36.80	x
2014-12-31	CN¥1.52	CN¥36.80	x
2015-12-31	CN¥1.85	CN¥36.80	x
2016-12-31	CN¥2.49	CN¥36.80	x
2017-12-31	CN¥6.67	CN¥36.80	x
2018-12-31	CN¥6.89	CN¥36.80	x
2019-12-31	CN¥7.50	CN¥36.80	x
2020-12-31	CN¥8.01	CN¥36.80	x
2021-12-31	CN¥8.14	CN¥36.80	x
2022-12-31	CN¥9.33	CN¥36.80	x
2023-12-31	CN¥10.36	CN¥36.80	x
2024-12-31	CN¥12.15	CN¥36.80	x
2025-12-31	CN¥11.78	CN¥36.80	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tibet Rhodiola Pharmaceutical Holding Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 24.69%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 31.79%
• Asset Turnover: 0.47x
• Equity Multiplier: 1.65x
Recent ROE (24.69%) is above the historical average (9.82%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1996	31.27%	25.84%	0.46x	2.64x	CN¥3.81 Million
1997	23.29%	41.16%	0.40x	1.40x	CN¥11.34 Million
1998	33.04%	40.91%	0.45x	1.79x	CN¥22.27 Million
1999	8.49%	39.87%	0.19x	1.12x	CN¥-5.90 Million
2000	7.73%	37.28%	0.16x	1.32x	CN¥-9.12 Million
2001	4.53%	24.51%	0.12x	1.51x	CN¥-22.12 Million
2002	2.46%	13.69%	0.10x	1.77x	CN¥-31.24 Million
2003	1.37%	7.69%	0.10x	1.80x	CN¥-36.24 Million
2004	1.43%	3.33%	0.24x	1.82x	CN¥-36.54 Million
2005	-10.74%	-5.93%	0.85x	2.13x	CN¥-79.81 Million
2006	1.05%	0.47%	0.99x	2.23x	CN¥-34.71 Million
2007	-46.53%	-15.22%	0.99x	3.09x	CN¥-152.19 Million
2008	2.35%	0.65%	1.19x	3.01x	CN¥-21.08 Million
2009	6.85%	1.82%	1.49x	2.52x	CN¥-9.27 Million
2010	7.37%	2.12%	1.51x	2.30x	CN¥-8.39 Million
2011	6.03%	1.90%	1.37x	2.32x	CN¥-13.48 Million
2012	8.21%	2.50%	1.45x	2.27x	CN¥-6.63 Million
2013	6.99%	1.94%	1.23x	2.93x	CN¥-11.71 Million
2014	5.19%	1.26%	1.59x	2.59x	CN¥-19.46 Million
2015	18.72%	6.63%	1.96x	1.44x	CN¥42.69 Million
2016	30.01%	24.89%	0.35x	3.47x	CN¥132.23 Million
2017	11.24%	25.08%	0.39x	1.14x	CN¥25.33 Million
2018	9.57%	20.98%	0.41x	1.12x	CN¥-9.64 Million
2019	12.82%	24.87%	0.45x	1.14x	CN¥68.62 Million
2020	16.23%	30.45%	0.47x	1.14x	CN¥160.49 Million
2021	7.94%	9.77%	0.56x	1.45x	CN¥-54.10 Million
2022	12.28%	14.48%	0.62x	1.36x	CN¥68.67 Million
2023	23.95%	25.55%	0.68x	1.37x	CN¥466.46 Million
2024	26.83%	37.46%	0.59x	1.21x	CN¥659.51 Million
2025	24.69%	31.79%	0.47x	1.65x	CN¥558.09 Million

Industry Comparison

This section compares Tibet Rhodiola Pharmaceutical Holding Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,041,443,343
Average return on equity (ROE) among peers: 10.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Tibet Rhodiola Pharmaceutical Holding Co (600211)	CN¥4.23 Billion	31.27%	0.51x	$1.74 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$971.04 Million	5.41%	3.98x	$565.97 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.33 Billion	6.10%	1.68x	$359.03 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$8.39 Billion	22.09%	0.19x	$4.30 Billion
Livzon Pharmaceutical Group Inc (000513)	$3.01 Billion	11.93%	0.53x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$2.41 Billion
Yunnan Baiyao Group Co Ltd (000538)	$1.42 Billion	23.64%	1.01x	$12.64 Billion
Hainan Haiyao Co Ltd (000566)	$445.29 Million	14.73%	0.90x	$715.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$347.80 Million	3.58%	0.72x	$319.94 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$905.53 Million	2.15%	1.95x	$916.75 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$22.44 Billion	6.25%	0.15x	$3.00 Billion

About Tibet Rhodiola Pharmaceutical Holding Co

SHG:600211 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.74 Billion

CN¥11.86 Billion CNY

Market Cap Rank

#6786 Global

#1505 in China

Share Price

CN¥36.80

Change (1 day)

+0.96%

52-Week Range

CN¥35.31 - CN¥56.43

All Time High

CN¥165.99